ImmunityBio’s $50.0 Million Offering

Goodwin Procter advised Jefferies LLC as exclusive placement agent on the deal. ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced that it has executed financing…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now